A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04648319|
Recruitment Status : Terminated (pharma company decision to withdraw the financial and IMP support)
First Posted : December 1, 2020
Last Update Posted : February 23, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cholangiocarcinoma||Drug: BMS-936558||Phase 2|
The current standard regimen for advanced biliary tract cancers as per NCCN guidelines (version 2.2019) is gemcitabine plus cisplatin. However, since no single chemotherapy agent or combination regimen has consistently led to durable tumor regression, prevention of recurrent obstruction following palliative intervention, and extension of survival beyond 8 to 15 months, there is a pressing need for new treatment approaches in patients with dismal prognosis. Recent discoveries in tumor immunology, paralleled by technological advances in radiation therapy, have provided promising role for combining ablative radiotherapy with targeted immune modulators (El Chediak et al., 2017).
objectives: Primary: To evaluate the progression-free survival (PFS) at 8 months and the disease control rate (DCR) in patients with non-resectable locally-advanced or metastatic or recurrent intrahepatic or extrahepatic cholangiocarcinoma (CCA) following BMS-936558 /stereotactic ablative radiation therapy (SBRT) treatment.
1) To evaluate the overall survival (OS) rate in patients with advanced intrahepatic or extrahepatic CCA following BMS-936558/SBRT treatment. .
3) To evaluate tumor response rates at the primary and secondary sites using the response evaluation criteria in solid tumors (RECIST1.1) criteria.
4) To evaluate the duration of response at non-irradiated tumor sites in patients with Stage IV disease.
5) To evaluate the following biomarkers: CD3+, CD4+, and CD8+ T cell infiltration, and changes in PD-L1 expression at baseline and following first cycle of BMS-936558 and SBRT.
6) To assess the safety and tolerability of BMS-936558/SBRT according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAEv5).
7) To assess the quality of life of the patients through completed FACT-Hep questionnaires.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||single group assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of BMS-936558 With Stereotactic Ablative Radiation Therapy After Induction Chemotherapy in Cholangiocarcinoma|
|Actual Study Start Date :||April 15, 2021|
|Actual Primary Completion Date :||January 17, 2022|
|Actual Study Completion Date :||January 17, 2022|
Experimental: locally advanced, metastatic or recurrent cholangiocarcinoma
D1: Compound: BMS-936558 treatment d8: radiotherapy D 20: CT guided Biopsy D 28: BMS-936558 treatment monthly: BMS-936558 treatment CT CAP: after 4doses
BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
Other Name: radiation therapy : SBRT
- To evaluate the progression-free survival (PFS) at 8 months and the disease control rate (DCR) in patients with non-resectable locally-advanced or metastatic or recurrent intrahepatic or extrahepatic CCA following BMS-936558/SBRT treatment [ Time Frame: 8 months ]will be done at 8 months of the initial patient diagnosis and after 8 cycles of treatment
- To evaluate the overall survival (OS) rate in patients with advanced intrahepatic or extrahepatic CCA following BMS-936558/SBRT treatment. [ Time Frame: up to 2 years ]survival status will be evaluated every 3 months after progression
- To evaluate tumor response rates at the primary and secondary sites using the response evaluation criteria in solid tumors (RECIST1.1) criteria. [ Time Frame: every 4 months from the date of first treatment visit until the date of first documented progression, assessed up to 2 years. ]evaluation will be done by CT scan of chest ,abdomen and pelvis every 4 months from the D1 ( after each 4 cycles of treatment until progression )
- To evaluate the duration of response at non-irradiated tumor sites in patients with Stage IV disease. [ Time Frame: every 4 months from the date of first treatment visit until the date of first documented progression, assessed up to 2 years. ]evaluation will be done by CT scan of abdomen, pelvis and chest every 4 months (after every 4 cycles of treatment until progression )
- To evaluate the following biomarkers: CD3+, CD4+, and CD8+ , and changes in PD-L1 expression at baseline and following first cycle of BMS-936558and SBRT. [ Time Frame: at baseline/inclusion visit and Day20 (after radiotherapy) ]
biomarkers will be assessed from baseline biopsy and after receiving first BMS-936558and SBRT for changes.
CD3+, CD4+, and CD8+: Will be quantified in mm2 in the most abundant tumor-infiltrating area in both, the stroma and the tumor, of the baseline biopsy (continuous variable) PD-L1: Will be evaluated on tumor cells and infiltrating immune T cells and be classified as negative or positive or not applicable (categorical variable)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Signed and dated informed consent form.
- Patients aged ≥18 years.
- Pathologically (histologically or cytologically) and radiologically confirmed diagnosis of non-resectable locally advanced or metastatic or recurrent intrahepatic or extrahepatic CCA within 90 days of registration.
- Patients who have stable disease or partial response following 4 cycles of cisplatin/gemcitabine.
ECOG performance score <3
o An estimated life expectancy of more than 3 months.
Have adequate hematologic and biochemical function by meeting the following:
- Total bilirubin acceptable level ≤ 1.5 × the institutional upper limit of normal (ULN) range;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) acceptable levels up to 5 x ULN range;
- Serum urea and serum creatinine acceptable levels up to 1.5 x ULN range;
- Calculated glomerular filtration rate ≥ 45 mL/min according to the Chronic Kidney Disease Epidemiology Collaboration equation (or local institutional standard method).
- Negative serum or urine pregnancy test at screening for women of childbearing potential who are sexually active.
- Highly effective contraception for both males and females of child-bearing potential who are sexually active throughout the study and for at least 5 months and 7 months after the last BMS-936558 treatment administration, respectively.
- Candidate for percutaneous biopsy as per tumor location evidenced by CT scan and interventional radiologist.
- Patients who have progression following 4 cycles of cisplatin/gemcitabine evidenced by CT scan as per RECIST 1.1.
- Active brain metastases or leptomeningeal metastases.
- Prior organ transplantation or allogenic stem-cell transplantation.
- Known prior severe hypersensitivity to IMP or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI-CTCAE v4.03 Grade ≥ 3).
- Active infection requiring systemic therapy within 28 days before the first dose of study treatment (e.g., urinary tract infection).
- Known history of testing positive for the human immunodeficiency virus or known acquired immunodeficiency syndrome.
- Evidence of liver cirrhosis.
Current use of immunosuppressive medication, except for the following:
- Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);
- Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Active autoimmune diseases that might deteriorate upon receiving an immune-stimulatory agent.
- Conditions such as vitiligo, psoriasis, diabetes type I, or hypo- or hyper-thyroid diseases not requiring immunosuppressive treatment are eligible.
- Commonly excluded conditions include: Addison's disease, thyroiditis/Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome, and Grave's disease
- Hepatic insufficiency manifesting as clinical jaundice, hepatic encephalopathy, and/or variceal bleed within 60 days prior to study entry.
- Transmural myocardial infarction within 6 months of enrollment; provided that anti-platelets cannot be stopped to perform percutaneous biopsy.
- Congestive heart failure (≥ New York Heart Association Classification Class II) requiring hospitalization within the last 6 months provided that anti-platelets cannot be stopped to perform percutaneous biopsy.
- Serious cardiac arrhythmia requiring medical treatment provided that anti-platelets cannot be stopped to perform percutaneous biopsy.
- Recent cerebral vascular accident/stroke within 6 months of enrollment provided that anti-platelets cannot be stopped to perform percutaneous biopsy.
- End-stage renal disease requiring dialysis.
- Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior.
- Vaccination within 4 weeks of the first dose of BMS-936558 and while on trial is prohibited except for administration of inactivated vaccines.
- Treatment with an investigational agent within 28 days before the first dose of study treatment.
- Prior treatment with any drug or antibody (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody) targeting T cell co-stimulation or checkpoint pathways.
- Patients suspected by the physician that he/she will not be compliant to the protocol conduct.
- Pregnant women are excluded from this study; breastfeeding should be discontinued.
- Patients participating in another clinical trial.
- Patients not willing to sign the consent form.
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Legal incapacity or limited legal capacity patients receiving other oncology specific medication not authorized in the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04648319
|Institut Jule Bordet|
|Brussels, Belgium, 1000|
|Cliniques universitaires Saint-Luc|
|Brussels, Belgium, 1200|
|American University of Beirut Medical Center|
|Centre hospitalier de Luxembourg|
|Principal Investigator:||Ali Shamseddine, MD||American University of Beirut Medical Center|
|Responsible Party:||American University of Beirut Medical Center|
|Other Study ID Numbers:||
CA209-7DJ ( Other Grant/Funding Number: CA209-7DJ )
|First Posted:||December 1, 2020 Key Record Dates|
|Last Update Posted:||February 23, 2022|
|Last Verified:||November 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action